Qi Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qi Shen has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
Jun Zhang
Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China
32 shared publicationsJie Yang
18 shared publicationsTiantian Zuo
School of Pharmacy Shanghai Jiao Tong University 800 Dongchuan Road Shanghai 200240 China
14 shared publicationsXiuhua Pan
School of Pharmaceutical Sciences, Shanghai Jiao Tong University, 200240, Shanghai, China
13 shared publicationsYawen Wei
School of Pharmacy Shanghai Jiao Tong University 800 Dong Chuan Road Shanghai 200240 China
11 shared publicationsRuixin Kang
School of Pharmaceutical Sciences, Shanghai Jiao Tong University, 200240, Shanghai, China
10 shared publications
Latest Publications
- 12 December 2025
- Published by Elsevier in Biomaterials
- Vol. 328, 123893
Programmable bacteria-driven biohybrid triggers spatiotemporal-controlled STING activation to potentiate cuproptosis-based cancer therapy
- 12 December 2025
- Published by Elsevier in Biomaterials
- Vol. 328, 123893
Programmable bacteria-driven biohybrid triggers spatiotemporal-controlled STING activation to potentiate cuproptosis-based cancer therapy
- 5 December 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 390, 114511
Self-lytic Nano-bacterial biohybrid reprograms Intratumoral microbiome–immune interactions for cancer immunotherapy
- 5 December 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 390, 114511
Self-lytic Nano-bacterial biohybrid reprograms Intratumoral microbiome–immune interactions for cancer immunotherapy
- 6 September 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 387, 114203
Outer membrane vesicle–coated ferrocene nanoparticles induce dual ferroptosis for cancer immunotherapy
- 6 September 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 387, 114203
Outer membrane vesicle–coated ferrocene nanoparticles induce dual ferroptosis for cancer immunotherapy
- 12 August 2025
- Published by Elsevier in Biomaterials
- Vol. 325, 123629
Eliminating intratumoral bacteria with cGAS-STING-activating nanodrug-bacteria biohybrids potentiates cancer immunotherapy
- 12 August 2025
- Published by Elsevier in Biomaterials
- Vol. 325, 123629
Eliminating intratumoral bacteria with cGAS-STING-activating nanodrug-bacteria biohybrids potentiates cancer immunotherapy
- 9 June 2025
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 699 (Pt 1) , 138158
Sustained-release hydrogel system for preventing postoperative tumor recurrence through synergistic immune signal enhancement for T cell activation
- 9 June 2025
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 699 (Pt 1) , 138158
Sustained-release hydrogel system for preventing postoperative tumor recurrence through synergistic immune signal enhancement for T cell activation
- Open Access
- 3 February 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (6)
Machine learning-assisted microfluidic approach for broad-spectrum liposome size control
- 3 February 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (6)
Open AccessMachine learning-assisted microfluidic approach for broad-spectrum liposome size control
- 2 October 2024
- Published by Wiley in Advanced Functional Materials
- Vol. 34 (51)
Self‐Adjuvanting Bacteria Hydrogel for SHP1 Checkpoint Inhibition in Tumor‐Draining Lymph Nodes to Enhance Cancer Immunotherapy
Despite recent advances in immunotherapy, its efficacy remains constrained by the absence of immune coordination. Especially, the interplay between tumor‐draining lymph nodes (TDLNs) and tumors is frequently disregarded. Here, a self‐adjuvanting hydrogel capable of eliciting a powerful and sustained immune response is developed. Briefly, the engineered arabinose response bacteria (ARB) expressing IL‐15 and mannose‐modified hollow mesoporous Prussian blue nanoparticles (NPs) loaded with vitamin E (Man/HMPB(VE), MHV) are mixed with arabinose hydrogel (AraGel), forming the system designated as AraGel@ARB/MHV (AAM). Employing mild photothermal therapy mediated by MHV, immunogenic cell death (ICD) triggers the release of tumor‐associated antigens. Subsequently, Man‐modified NPs target TDLNs and release VE, which suppresses the checkpoint Src homology region 2 domain‐containing phosphatase‐1 (SHP1) in dendritic cells, thereby enhancing antigen presentation and T cell activation. Meanwhile, IL‐15 expression of ARB(IL‐15) induced by AraGel degradation enables ARB to serve as an enhanced adjuvant in a self‐adjuvanting manner, working synergistically with ICD and TDLN reprogramming to promote cytotoxic T lymphocytes activation. The hydrogel system efficiently suppresses tumor growth by eliciting prolonged and powerful immunotherapy in an orchestrated manner. Overall, the self‐adjuvanting hydrogel holds great potential for cancer immunotherapy.
- 2 October 2024
- Published by Wiley in Advanced Functional Materials
- Vol. 34 (51)
Self‐Adjuvanting Bacteria Hydrogel for SHP1 Checkpoint Inhibition in Tumor‐Draining Lymph Nodes to Enhance Cancer Immunotherapy
Despite recent advances in immunotherapy, its efficacy remains constrained by the absence of immune coordination. Especially, the interplay between tumor‐draining lymph nodes (TDLNs) and tumors is frequently disregarded. Here, a self‐adjuvanting hydrogel capable of eliciting a powerful and sustained immune response is developed. Briefly, the engineered arabinose response bacteria (ARB) expressing IL‐15 and mannose‐modified hollow mesoporous Prussian blue nanoparticles (NPs) loaded with vitamin E (Man/HMPB(VE), MHV) are mixed with arabinose hydrogel (AraGel), forming the system designated as AraGel@ARB/MHV (AAM). Employing mild photothermal therapy mediated by MHV, immunogenic cell death (ICD) triggers the release of tumor‐associated antigens. Subsequently, Man‐modified NPs target TDLNs and release VE, which suppresses the checkpoint Src homology region 2 domain‐containing phosphatase‐1 (SHP1) in dendritic cells, thereby enhancing antigen presentation and T cell activation. Meanwhile, IL‐15 expression of ARB(IL‐15) induced by AraGel degradation enables ARB to serve as an enhanced adjuvant in a self‐adjuvanting manner, working synergistically with ICD and TDLN reprogramming to promote cytotoxic T lymphocytes activation. The hydrogel system efficiently suppresses tumor growth by eliciting prolonged and powerful immunotherapy in an orchestrated manner. Overall, the self‐adjuvanting hydrogel holds great potential for cancer immunotherapy.
- 26 June 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 372, 446-466
Biomimetic gold nanocages incorporating copper-human serum albumin for tumor immunotherapy via cuproptosis-lactate regulation
- 26 June 2024
- Published by Elsevier in Journal of Controlled Release
- Vol. 372, 446-466
Biomimetic gold nanocages incorporating copper-human serum albumin for tumor immunotherapy via cuproptosis-lactate regulation
- 29 February 2024
- Published by Elsevier in Nano Today
- Vol. 55
Biomimetic bacteria-derived nanoclusters enhance ferroptosis cancer immunotherapy through synergistic CRISPR-photothermo modulation
- 29 February 2024
- Published by Elsevier in Nano Today
- Vol. 55
Biomimetic bacteria-derived nanoclusters enhance ferroptosis cancer immunotherapy through synergistic CRISPR-photothermo modulation